Free Trial

Florida Financial Advisors LLC Acquires Shares of 21,277 ADMA Biologics Inc (NASDAQ:ADMA)

ADMA Biologics logo with Medical background

Florida Financial Advisors LLC bought a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 21,277 shares of the biotechnology company's stock, valued at approximately $423,000.

Other hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in ADMA Biologics during the fourth quarter valued at approximately $19,076,000. JPMorgan Chase & Co. lifted its position in ADMA Biologics by 272.5% during the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of ADMA Biologics by 52.8% in the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock worth $1,886,000 after acquiring an additional 38,002 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of ADMA Biologics by 147.2% in the 4th quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock worth $9,043,000 after acquiring an additional 314,013 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after acquiring an additional 108,800 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 in the last three months. 3.50% of the stock is owned by insiders.

ADMA Biologics Trading Down 5.3%

Shares of ADMA traded down $0.94 during mid-day trading on Friday, reaching $16.65. The company's stock had a trading volume of 1,931,716 shares, compared to its average volume of 3,649,274. The stock has a market cap of $3.98 billion, a PE ratio of 19.62 and a beta of 0.43. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 52 week low of $10.21 and a 52 week high of $25.67. The company's fifty day moving average price is $19.29 and its two-hundred day moving average price is $18.76.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter in the prior year, the company earned $0.08 earnings per share. The company's quarterly revenue was up 40.2% compared to the same quarter last year. On average, analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ADMA shares. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.

View Our Latest Stock Analysis on ADMA

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Read More

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Should You Invest $1,000 in ADMA Biologics Right Now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines